Why we must expand newborn screening
6 May 2021
Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.
University spinout PepGen awarded major financing to target Duchenne muscular dystrophy
9 December 2020
PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.
MDUK ONMC Professor, Angela Russell, awarded the 2021 Harrington UK Rare Disease Scholar Award
15 October 2020
The Harrington Discovery Institute (HDI) in the US has announced five winners of its inaugural UK Rare Disease Scholar Award competition, including a key investigator of the MDUK Oxford Neuromusuclar Centre, Professor Angela Russell.
Two MDUK ONMC professors honoured by the Academy of Medical Sciences
13 May 2020
The Academy of Medical Sciences, the independent body in the UK representing the diversity of medical science, has announced the election of fifty new Fellows, including two academics from the MDUK Oxford Neuromuscular Centre.
The MDUK Oxford Neuromuscular Centre's First Annual Scientific Meeting
19 February 2020
The Centre hosted a very successful first annual scientific meeting on 12 February 2020 at St Anne’s College, Oxford, including all research groups in the Centre as well as a panel of international experts in the field.
A new research centre tackles neuromuscular diseases
11 November 2019
The launch of the MDUK Oxford Neuromuscular Centre marks an exciting new stage in the partnership between Muscular Dystrophy UK and the University of Oxford, with the goal of delivering new experimental medicines and developing enhanced clinical trial capacity in adult and paediatric neuromuscular diseases.
First steps towards treating myotonic dystrophy type 1
18 September 2019
Collaborative research between teams from the Department of Paediatrics and the Institut de Myologie shows how antisense oligonucleotides can penetrate muscles to treat myotonic dystrophy type 1, a rare muscle disease.
NHS England to fund Spinraza drug, treating children with Spinal Muscular Atrophy
22 May 2019
Spinraza – the first treatment for the rare condition spinal muscular atrophy (SMA) – is set to be available for NHS use for children and adults with SMA Types 1, 2 and 3.
Bake Sale for MDUK Oxford Town and Gown Support
1 April 2019
MDUK Oxford Neuromuscular Centre Researchers Raise Funds for their runners in the MDUK Oxford Town and Gown
World-leading neurologist appointed to Professorship at MDUK Oxford Neuromuscular Centre
25 March 2019
Acclaimed clinical researcher, Professor Laurent Servais, has been appointed Professor of Paediatric Neuromuscular Diseases at the MDUK Oxford Neuromuscular Centre.
MDUK-Oxford University partnership
1 February 2019
Changing the landscape for clinical trials by developing a major centre in the UK.